Merck & Company Inc (MRK)vsNervGen Pharma Corp. (NGEN)
MRK
Merck & Company Inc
$120.79
-1.42%
HEALTHCARE · Cap: $285.64B
NGEN
NervGen Pharma Corp.
$2.01
+5.24%
HEALTHCARE · Cap: $197.54M
Smart Verdict
WallStSmart Research — data-driven comparison
MRK leads profitability with a 13.6% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 50/100 (D+).
MRK
Hold50
out of 100
Grade: D+
NGEN
Avoid16
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Intrinsic value data unavailable for NGEN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
No standout strengths identified
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : NGEN
NGEN has a balanced fundamental profile.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : NGEN
The primary concerns for NGEN are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
NGEN carries more volatility with a beta of 0.88 — expect wider price swings.
MRK is growing revenue faster at 4.9% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (50/100 vs 16/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →NervGen Pharma Corp.
HEALTHCARE · BIOTECHNOLOGY · USA
NervGen Pharma Corp. (NGEN) is an innovative biotechnology company focused on addressing unmet medical needs in the field of neurodegenerative diseases through its proprietary platform, which leverages nerve regeneration technology. The company is committed to the research and development of novel therapeutics aimed at restoring nerve function and improving patient outcomes for conditions like multiple sclerosis and spinal cord injuries. With a strategic emphasis on advancing its clinical programs and enhancing its intellectual property portfolio, NervGen is well-positioned to capitalize on the growing demand for effective treatments in the neurology sector, fostering potential long-term growth and value creation for investors.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?